Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study

Am J Clin Nutr. 2015 Apr;101(4):870-8. doi: 10.3945/ajcn.114.097923. Epub 2015 Jan 14.

Abstract

Background: Abdominal obesity and exaggerated postprandial lipemia are independent risk factors for cardiovascular disease (CVD) and mortality, and both are affected by dietary behavior.

Objective: We investigated whether dietary supplementation with whey protein and medium-chain saturated fatty acids (MC-SFAs) improved postprandial lipid metabolism in humans with abdominal obesity.

Design: We conducted a 12-wk, randomized, double-blinded, diet intervention study. Sixty-three adults were randomly allocated to one of 4 diets in a 2 × 2 factorial design. Participants consumed 60 g milk protein (whey or casein) and 63 g milk fat (with high or low MC-SFA content) daily. Before and after the intervention, a high-fat meal test was performed. We measured changes from baseline in fasting and postprandial triacylglycerol, apolipoprotein B-48 (apoB-48; reflecting chylomicrons of intestinal origin), free fatty acids (FFAs), insulin, glucose, glucagon, glucagon-like peptide 1 (GLP-1), and gastric inhibitory polypeptide (GIP). Furthermore, changes in the expression of adipose tissue genes involved in lipid metabolism were investigated. Two-factor ANOVA was used to examine the difference between protein types and fatty acid compositions, as well as any interaction between the two.

Results: Fifty-two participants completed the study. We found that the postprandial apoB-48 response decreased significantly after whey compared with casein (P = 0.025) independently of fatty acid composition. Furthermore, supplementation with casein resulted in a significant increase in the postprandial GLP-1 response compared with whey (P = 0.003). We found no difference in postprandial triacylglycerol, FFA, insulin, glucose, glucagon, or GIP related to protein type or MC-SFA content. We observed no interaction between milk protein and milk fat on postprandial lipemia.

Conclusion: We found that a whey protein supplement decreased the postprandial chylomicron response compared with casein in persons with abdominal obesity, thereby indicating a beneficial impact on CVD risk. This trial was registered at clinicaltrials.gov as NCT01472666.

Keywords: abdominal obesity; adipose tissue gene expression; apoB-48; casein; dairy; incretin; medium-chain saturated fatty acid; milk fat; milk protein; postprandial lipemia; whey.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Apolipoprotein B-48 / blood
  • Blood Glucose / metabolism
  • Caseins / administration & dosage
  • Chylomicrons / blood
  • Dairy Products*
  • Dietary Fats / administration & dosage*
  • Dietary Proteins / administration & dosage*
  • Dietary Supplements
  • Double-Blind Method
  • Fatty Acids, Nonesterified / blood
  • Female
  • Gastric Inhibitory Polypeptide / blood
  • Glucagon / blood
  • Glucagon-Like Peptide 1 / blood
  • Humans
  • Hyperlipidemias / diet therapy*
  • Insulin / blood
  • Lipid Metabolism*
  • Male
  • Meals
  • Middle Aged
  • Milk Proteins / administration & dosage
  • Nutrition Assessment
  • Obesity, Abdominal / diet therapy*
  • Postprandial Period
  • Triglycerides / blood
  • Whey Proteins

Substances

  • Apolipoprotein B-48
  • Blood Glucose
  • Caseins
  • Chylomicrons
  • Dietary Fats
  • Dietary Proteins
  • Fatty Acids, Nonesterified
  • Insulin
  • Milk Proteins
  • Triglycerides
  • Whey Proteins
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1
  • Glucagon

Associated data

  • ClinicalTrials.gov/NCT01472666